Soc. Int. Urol. J., Volume 5, Issue 6 (December 2024) – 4 articles

Introduction: The integration of laser technology in urologic interventions, especially ureteral lithotripsy, has greatly advanced the field, with laser lithotripsy becoming the preferred method for treating ureteric stones via ureteroscopy. Recent advancements focus on enhancing power settings and reducing operating times, introducing high-power laser equipment capable of frequencies up to 120 Hz. However, concerns arise regarding thermal injuries to adjacent tissues due to increased energy delivery, potentially causing ureteric strictures. Objective: To explore temperature dynamics during ureteroscopic laser lithotripsy, considering factors like laser power settings and ureteroscope size, to optimize outcomes and mitigate risks for patients. Methods: A simulated in vitro model for ureteroscopic laser lithotripsy was designed with a holmium laser. Measurements of the temperature were recorded using a thermocouple placed at the laser tip at different sizes of ureteroscope (URS 6.0 Fr and URS 7.0 Fr), holmium laser (272 µm and 365 µm), various power settings (5 to 25 Hz; 0.2 to 3.0 J) and activation durations (3 to 30 s). Analysis of the variables associated with temperature change was performed. Results: All of the variables showed rising temperature trends as the laser activation time was prolonged, while ureteroscope size had no significant impact. Smaller laser fibers exhibited lower overall temperature profiles, around 34–35 °C. Notably, power settings significantly influenced temperature, with a substantial rise at 20 W (42.62 °C) and 30 W (40.02 °C). There was a significant rise in temperature as power (J × Hz) increased, where frequency carries a higher effect than energy at the same power setting. Conclusions: The recommendation includes exercising caution with higher power levels, shorter activation times, and preferably using small-caliber laser fibers to maintain lower temperatures. Full article

Background: Benign prostatic hyperplasia (BPH) is a frequent condition in ageing men. Surgery is recommended for severe BPH symptoms and BPH-related complications. TURP is the reference standard for BPH surgery, but carries a risk of bleeding, which can lead to significant perioperative morbidity and mortality. To reduce bleeding during TURP, antifibrinolytic agents like tranexamic acid (TXA) have been studied. We aim to review the current evidence regarding TXA use during transurethral BPH surgery. Objective: This review aims to assess the efficacy and safety of tranexamic acid in reducing bleeding during transurethral benign prostatic hyperplasia surgery. Methods: Major clinical research databases such as PubMed, Cochrane Central Register of Controlled Trials, EBSCO, Scopus, Google Scholar, and Web of Science were searched from 2012 to 2022 for randomised controlled trials (RCTs) comparing the use of TXA to placebo in transurethral BPH surgery using the PICOS format. We included RCTs without language restrictions that assessed intraoperative blood loss, transfusion rates, haemoglobin levels, length of hospital stay, postoperative thromboembolic events, and 30-day perioperative mortality as outcomes. The quality assessment of the included studies was performed using the Cochrane risk-of-bias tool, RoB 2, for randomised studies. Results: A total of six RCTs, which included 456 patients, were eventually included in the meta-analysis. The results showed that tranexamic acid is beneficial in reducing blood loss and minimising changes in haemoglobin levels during transurethral resection of the prostate. However, it does not lessen the need for blood transfusions or shorten the hospital stay. Conclusions: Tranexamic acid is useful in decreasing blood loss and reducing changes in haemoglobin in patients undergoing transurethral resection of the prostate. Its utility during BPH surgery in low-resource settings where the latest haemostatic enucleation techniques, such as holmium and GreenLight laser enucleation, may not be readily available needs further evaluation. Full article

Background: Across the world, many populations have limited access to urology care resulting in local general surgeons performing emergency urology procedures. This systematic review aims to evaluate the nature and outcomes of emergency urological surgeries performed by general surgeons. Methods: A systematic review was undertaken according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines with MEDLINE, Embase, Web of Science, and Google Scholar searched from inception to June 2024 for studies where general surgeons performed emergent urological surgery. We excluded studies on paediatric urology, acute scrotum, and Fournier’s gangrene. The Downs and Black checklist was used to assess risk of bias. Results: From 2093 initial results, six studies were included after screening. Two studies were from Australia, two from the United States of America, and one each from India and South Africa. For 977 emergency urological interventions, general surgeons (n = 486) and urologists (n = 491) each performed approximately half of the surgeries. Mortality rates for general surgeon-performed urology ranged from 0 to 8.0%. One study compared outcomes between the two surgical specialties, showing no significant difference for mortality or complication rates. No follow-up data was reported. The most performed procedures by general surgeons were traumatic bladder repair, ureteric stent insertion, and percutaneous nephrostomy. Conclusions: General surgeons perform a wide spectrum of emergency urological surgery when needed. Targeted training and utilisation of general surgeons could improve patient access to emergency urological surgery. Full article